
Mechanism of SHED-derived HGF in treating chronic perinatal brain injury
Illustration Credit: Yoshiaki Sato
Scientific Frontline: "At a Glance" Summary: Stem Cells for Treating Cerebral Palsy
- Main Discovery: Researchers demonstrated that stem cells derived from human exfoliated deciduous teeth effectively treat cerebral palsy in animal models, even when administered during the chronic phase after motor deficits have already emerged.
- Methodology: The research team induced unilateral hypoxic-ischemic brain injury in seven-day-old rats to mimic hemiplegic cerebral palsy and administered the stem cells intravenously at five, seven, and nine weeks of age. They subsequently evaluated the subjects using horizontal ladder, cylinder, and shuttle avoidance tests to assess both motor and cognitive functions.
- Key Data: Rats treated with the stem cells exhibited a significantly lower number of slips on the horizontal ladder test at four months, relied more on their impaired forelimbs, and demonstrated superior learning and memory in shuttle avoidance tests compared to the untreated control group.
- Significance: This marks the first animal study to prove that stem cell therapy can restore neurological function and promote new nervous tissue growth via hepatocyte growth factor in the later stages of cerebral palsy, successfully circumventing the ethical concerns associated with other stem cell sources.
- Future Application: Clinical studies are currently evaluating the safety and tolerability of intravenous autologous stem cell doses in children with cerebral palsy, with plans for large-scale trials to establish this approach as a standard clinical treatment option.
- Branch of Science: Regenerative Medicine, Pediatrics, and Neurology.
.jpg)


.jpg)


%20(resized).jpg)
.jpg)
